Caxton Associates LP Buys Shares of 18,875 Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Caxton Associates LP purchased a new position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 18,875 shares of the company’s stock, valued at approximately $117,000.

Several other institutional investors and hedge funds have also modified their holdings of FULC. National Bank of Canada FI raised its holdings in Fulcrum Therapeutics by 869.6% in the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after purchasing an additional 4,000 shares during the period. Capstone Investment Advisors LLC bought a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $68,000. Profund Advisors LLC purchased a new position in shares of Fulcrum Therapeutics during the 2nd quarter valued at about $68,000. Renaissance Technologies LLC bought a new position in shares of Fulcrum Therapeutics during the 2nd quarter valued at approximately $82,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Fulcrum Therapeutics by 66.7% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company’s stock worth $112,000 after acquiring an additional 4,766 shares in the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Price Performance

NASDAQ FULC opened at $3.77 on Friday. Fulcrum Therapeutics, Inc. has a 1-year low of $2.87 and a 1-year high of $13.70. The business has a 50 day simple moving average of $7.56 and a two-hundred day simple moving average of $7.74. The stock has a market capitalization of $234.32 million, a PE ratio of -2.36 and a beta of 2.23.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.93. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%. The firm had revenue of $80.00 million during the quarter, compared to the consensus estimate of $80.00 million. During the same period in the prior year, the company earned ($0.38) EPS. On average, analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

FULC has been the topic of several analyst reports. HC Wainwright downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the company from $17.00 to $4.00 in a report on Friday, September 13th. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a report on Thursday, September 12th. Stifel Nicolaus cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the company from $22.00 to $3.00 in a report on Thursday, September 12th. Leerink Partnrs lowered Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Finally, Bank of America downgraded Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and decreased their target price for the company from $10.00 to $2.00 in a research note on Thursday, September 12th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $9.33.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.